| Grab Sources And More: INBS Website. INBS Presentation. -----
And based on multiple potential catalysts mentioned above, (Nasdaq: INBS) has quickly risen the ranks to the top spot on my watchlist. Check them out:
#1. INBS Potential Catalyst - A Low Float Could Create Heightened Volatility In A Flash.
According to info from the Yahoo Finance website, INBS has a fairly low float.
In fact, the website reports this profile to have approx. 5.17Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If the company provides more positive company news in the first half of 2025, could it provide a near term spark? -----
#2. INBS Potential Catalyst - A Multitude Of Triggered Technicals Could Generate Breakout Buzz!
On Monday at 1:00PM EST, Barchart was reporting several triggered technical indicators across the short, medium, and long term for INBS.
Here's their list (as of 1:00PM EST Monday):
Short Term Indicators
- 20 - 50 Day MA Crossover
- 20 - 100 Day MA Crossover
- 20 - 200 Day MA Crossover
Medium Term Indicators
- 50 Day Moving Average
- 50 - 100 Day MA Crossover
- 50 - 150 Day MA Crossover
- 50 - 200 Day MA Crossover
Long Term Indicators
- 100 Day Moving Average
- 150 Day Moving Average
- 200 Day Moving Average
- 100 - 200 Day MA Crossover
The website also shares its all-important "Trend Seeker" composite indicator is triggered as well.
Make sure to watch these technical indicators closely moving forward. -----
#3. INBS Potential Catalyst - Financial Results Suggest Company's "Business Model Is Excelling."
Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements
Gross pro-fit increase of 32.6% and 11-point gross pro-fit margin increase driven by higher-margin cartridge sales
Submitted FDA 510(k) and remain on track for planned expansion into multi-Bn dollar U.S. market in 2025
Added strategic partnerships, increasing visibility across the Asia-Pacific Region and the U.S.
Secured 19 accounts during quarter, adding to 400+ active customer accounts in 19 countries
NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal second quarter and six months ended December 31, 2024, and provided a business update.
"Fiscal Q2 was a successful quarter for the business in a number of areas. From a financial standpoint, our business model is excelling, with higher-margin cartridge sales steadily increasing, contributing to our gross pro-fit and margin growth. Our focus on deal size and growing the volume of cartridge sales has resulted in an 11-point increase in our gross pro-fit margin," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "From a regulatory standpoint, our clinical studies returned strong results, and we achieved a significant milestone with the submission of our FDA 510(k) package in December. We remain on track to enter the multi-Bn dollar U.S. market this year, and look forward to the opp's this will present for the business. In addition, we successfully executed on our international expansion plans, adding key strategic partnerships in the Asia-Pacific Region and the U.S."
"Our performance over the first half of fiscal 2025 shows that our focus on growing cartridge sales is translating to higher gross pro-fit and margins. We were pleased that gross pro-fit grew to 32.6% while gross profit margins increased to 38.5% from 27.7% for the six months ended December 31, 2024, year-over-year, showing that we have made strides in sustaining the Company’s long-term financial strength," said Spiro Sakiris, CFO at Intelligent Bio Solutions. “We expect cartridge sales to continue outpacing reader sales moving forward, maximizing our recurring revenue. We also continued to scale our customer base of over 400 accounts and expand our international presence, which we expect will continue to grow as we enter the U.S. market this year.”
...
Read the full article here. -----
#4. INBS Potential Catalyst - Key Expansion Underway With Game-Changing UK Partnership.
Intelligent Bio Solutions Expands with UK Partnership, Driving Global Growth Ahead of Planned U.S. Launch
Avon Freight Group selects INBS’ fingerprint drug testing for three UK sites, reinforcing workplace safety and efficiency
INBS surpasses 400+ accounts in 19 countries, targeting aggressive U.S. expansion in 2025 following FDA 510(k) submission
UK drug testing market projected to hit $453Mn by 2030, positioning INBS as a scalable, cost-effective industry leader
NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Avon Freight Group ("Avon") has selected its non-invasive Intelligent Fingerprinting Drug Testing Solution for random drug testing across its three UK sites, supporting proactive risk management and employee well-being. The addition of Avon further expands INBS’ client network of over 400 accounts in 19 countries.
...
Martin Bullimore, Commercial & Procurement Contracts Manager at Avon Freight Group, commented, "We've never had an in-house testing solution before, and moving to fingerprint drug testing is a big step forward for us. We recognized the need for a more proactive approach to workplace testing and appreciated the non-invasive nature of this solution. The system allows us to conduct random testing without disrupting operations or imposing on our employees' personal lives and reinforces our commitment to a safe, effective, and respectful workplace. The feedback has been extremely positive overall, with many stakeholders realizing its value.”
As more businesses in the logistics and transport sector recognize the limitations of traditional drug screening methods, solutions such as INBS' Drug Screening System are increasingly becoming the preferred choice. Market research estimates the UK Drug of Abuse Testing Services Market to be the fastest-growing regional market in Europe, projected to reach $453Mn by 2030. INBS is well-established and positioned to satisfy this growing demand with its scalable and cost-effective solution.
...
Read the full article here. -----
#5. INBS Potential Catalyst - A New Fruitful Partnership Expands Reach Across Europe And The Middle East.
Intelligent Bio Solutions Partners with IVY Diagnostics to Expand in Europe’s $3.6Bn Drug Screening Market and in Middle Eastern Regions
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), ..., today announced the strengthening of its foothold throughout Europe and the Middle East through its partnership with IVY Diagnostics Srl (“IVY Diagnostics”). As a key distributor, IVY Diagnostics is playing an integral role in expanding the adoption of INBS' Intelligent Fingerprinting Drug Testing Solution across Europe and the Middle East, with a particular focus on drug rehabilitation and law enforcement applications.
According to Grand View Research, the European and Middle Eastern drug screening markets are projected to grow significantly by 2030, with Europe expected to reach $3.6Bn and the Middle East and Africa $432.7Mn. This growing demand emphasizes the strategic importance of INBS' partnership with IVY Diagnostics.
...
"Our strategic partnership with IVY Diagnostics plays a key role in introducing our fingerprint sweat-based drug screening technology to new markets and industries," said Doug Heath, Vice President of Global Sales at Intelligent Bio Solutions. "Their deep understanding of the regulatory landscape, coupled with their extensive connections across Europe and the Middle East, positions them as an invaluable partner in our mission to provide safer and more efficient drug testing solutions worldwide."
...
Read the full article here. -----
(Nasdaq: INBS) Recap - 5 Potential Catalysts Lead The Way
#1. A Low Float Could Create Heightened Volatility In A Flash.
#2. A Multitude Of Triggered Technicals Could Generate Breakout Buzz!
#3. Financial Results Suggest Company's "Business Model Is Excelling."
#4. Key Expansion Underway With Game-Changing UK Partnership.
#5. A New Fruitful Partnership Expands Reach Across Europe And The Middle East.
-----
Coverage is officially initiated on Intelligent Bio Solutions Inc. (Nasdaq: INBS).
I'll be in touch with updates as the week moves on. Talk again soon.
Sincerely, FierceAnalyst | Jaks Swift Editorial Writer
Sources: (1)(2)
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 03/24/2025 and ending on 03/25/2025 to publicly disseminate information about (INBS:US) via digital communications. Under this agreement, SWN Media LLC has been paid fifteen thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (INBS:US).
Please see important disclosure information here: https://fierceinvestor.com/disclosure/inbs/#details | 
Tidak ada komentar:
Posting Komentar